Overview
| Name | MolE · aliases: MolE |
|---|---|
| Full name | The paper gives no expanded name |
| Ambiguous names (not auto-linked) | MolE model, Mole |
| Family | Not a family entry. The sibling successor MiniMol has its own record; no family entry |
| Organization | Recursion |
| Organization type | AI-native biotech |
| Country | United States |
| Model class | Property prediction (molecular-graph foundation model) |
| Domain | Small molecules |
| First release | · paper revision Basis: arXiv 2211.02657 v1 submitted Note: The site treated the 2024-11 journal publication as the release; first release follows the preprint v1 source |
| Other milestones | |
| Latest update | · journal Basis: Journal publication Journal publication; the public code repository's first commit was 2024-10-04 and the last around 2025-06. This is the latest sourced substantive event source The most recent sourced event, not a claim that nothing changed since. |
| Status | Maintained only · Only maintenance commits since publication, and a successor model exists |
| Openness | Code: Open · CC-BY-NC Weights: Closed Code is open for non-commercial use and the full pretrained weights are not released; a third-party container offers a smaller pretrained checkpoint |
| Benchmarks reported | 1 counted (board 1) |
| Wet-lab validation | None recorded |
| Unverified fields | † benchmarks_reported[0], release_milestones.code_release, background.products_partnerships |
| As of | 2026-11-16 |
What it does
Works directly on molecular graphs with atom identities as tokens and graph topological distance as relative position, pretraining first self-supervised (masking atoms and predicting their neighbourhood) and then with graph-level supervision, for downstream property and activity prediction. The sibling successor MiniMol self-reports better results on most comparable tasks with roughly a tenth of the parameters, which makes this model a reference point alongside ADMET-AI and KERMT in ADMET work.
Benchmarks reported
Every row is one pairing from the survey's relation file; a score belongs to the benchmark page's ranking, where it is shown with metric, eval set, source type and date. 1 of 1 pairings are counted.
| Benchmark | Relation | Eval set / protocol | Source type | Note and evidence |
|---|---|---|---|---|
| 04 TDC (ADMET + DTI) | Official leaderboard or results | — | Board | Paper compares with a 2023-09 board snapshot; no row on the live boards †partly verified · evidence |
Other evaluations (outside the 44)
- Pretraining scale ablation (Own task set) Self-reported: Controls on smaller molecular-graph subsets assessing how self-supervised scale affects downstream tasks; author-reported
- Comparison against classical baselines (Comparison against baselines only) Self-reported: On some tasks fingerprint plus gradient-boosting baselines remain competitive, a point made both by the authors and by later work
Developers report: moving disentangled attention to molecular graphs with two-stage pretraining beat the then-published best results on most tasks of a public ADMET task group (the comparison is a 2023-09 board snapshot).
Independent evidence: No independent evidence found. No independent third-party evaluation was found; the successor's comparison comes from the same organisation and is not independent
Training data
Group in Figure 7: Public data only.
| Class | Value | Detail |
|---|---|---|
| a. Public databases | Yes | Self-supervised on about 842 million molecular graphs from a public compound library (with smaller subsets as controls), then supervised pretraining on about 456,000 molecules with labels from a public bioactivity database source |
| b. Private or licensed data | No | source |
| c. Own wet-lab data used for training | No | |
| d. Wet lab used only for validation | No | The paper reports no wet-lab validation source |
Wet-lab validation
None. The developers report no wet-lab validation.
Background
- Organization: The developer is an AI-native biotech founded in Salt Lake City in 2013-11 and listed on Nasdaq in 2021-04, grown out of machine learning on high-content cell microscopy; it completed the acquisition of a UK AI drug-design company on 2024-11-20, after which headcount figures differ by source (roughly 600 to 800). Its machine-learning research centre launched 2023-07.
- Funding: A listed company. In 2023-07 a GPU vendor invested $50 million through a private placement alongside a foundation-model collaboration.
- Products and partnerships: Drug-discovery collaborations with two large pharma companies (from 2021-12 and 2023-09; announcements through 2026-08 report over $200 million in upfront and milestone payments received). A trade outlet says this model was released jointly with a Danish pharma company while the paper's affiliations read differently; the two accounts do not agree. A new chief executive took office 2026-01-01.
- Related models: MiniMol, ADMET-AI, KERMT
Reading notes
- The "first on most tasks" claim belongs to its 2024 paper and a 2023-09 board snapshot only: this round's sweep of all 22 official sub-task leaderboards found no row for the model, so it cannot be presented as a current board position.
- Preprint and journal versions count differently, showing how sensitive such rankings are to the snapshot date.
- The full weights are not released, so outsiders cannot reproduce the whole model and must use a third-party smaller checkpoint.
- On some TDC tasks classical fingerprint methods remain competitive, so a task-group ranking is not a general advantage.
Caveats
- No row for the model was found on the official sub-task leaderboards, so the board relation is shown as unverified.
- The comparison is a 2023-09 board snapshot and has since been surpassed.
- The full pretrained weights are not released.
- Media and paper accounts disagree on which organisations co-released the model.
Sources
- Journal paper 2024 (journal)
- Journal full text (public archive) (journal)
- Preprint v1 (preprint)
- Code repository (repository)
- Official task-group leaderboard overview (basis of this round's check) (leaderboard)
Corrections
2 corrections
| Field | Was | Now | Basis | Found |
|---|---|---|---|---|
| benchmarks_reported | First on 10 of 22 tasks (stated as a leaderboard position) | The claim belongs only to its 2024 paper and a 2023-09 snapshot; a full scan of the 22 official per-task boards found no row for it, so it is not a current leaderboard position | source | 2026-11-16 |
| first_release | 2024-11 (journal publication) | 2022-11-03(arXiv v1) | source | 2026-11-16 |
Part of the AI for Bio benchmarks survey · all 112 models · open in the explorer. Record as of 2026-11-16.